NCT03205033View on ClinicalTrials.gov

Melatonin as a Circadian Clock Regulator, Neuromodulator and Myelo-protector in Adjuvant Breast Cancer Chemotherapy

PHASE2CompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

January 31, 2016

Primary Completion Date

January 31, 2017

Study Completion Date

January 31, 2017

Conditions
Sleep Disorders, Circadian RhythmDepressionGenotoxicityPain
Interventions
DRUG

Melatonin 20 MG Oral Capsule

1 capsule/day 1 hour before go to bed

DRUG

Placebo oral capsule

1 capsule/day 1 hour before go to bed

All Listed Sponsors
lead

Hospital de Clinicas de Porto Alegre

OTHER

NCT03205033 - Melatonin as a Circadian Clock Regulator, Neuromodulator and Myelo-protector in Adjuvant Breast Cancer Chemotherapy | Biotech Hunter | Biotech Hunter